RANCHO CUCAMONGA, Calif., April 11, 2016 -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 12:50 p.m. Eastern Daylight Time in New York, NY.
This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com/events.cfm. This webcast will be available for 90 days following the presentation.
About Amphastar:
Amphastar is a specialty pharmaceutical company established in 1996 that primarily develops, manufactures, markets, and sells generic and proprietary injectable and inhalation products, including products with high technical barriers to market entry. Most of the Company’s products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. We currently produce approximately 16 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. Amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the U.S. enables it to establish significant market share upon the introduction of its new products.
Please visit us online at http://www.amphastar.com/index.html for more Company information.
Forward-Looking Statement:
This press release contains forward-looking statements, including statements relating to Amphastar Pharmaceuticals. These statements are not historical facts but rather are based on Amphastar Pharmaceuticals’ current expectations, estimates and projections regarding Amphastar Pharmaceuticals’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements. These statements are only predictions and as such are not guarantees of future performance, and they involve risks, uncertainties, and assumptions that are difficult or impossible to predict. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in Amphastar Pharmaceuticals’ filings with the SEC.
Contact: William J. Peters Chief Financial Officer (909) 476-3416


Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 



